Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression: (Consensus Statement)
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments. EVIDENCE: The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings. CONSENSUS PROCESS: In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion." CONCLUSIONS: Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repetitive transcranial magnetic stimulation (rTMS) is an effective method used in clinical practice for treating patients with MDD. 408”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [408]
In the citing paper
“Most clinical rTMS treatments for MDD occur daily (one rTMS session per day) and are applied using scalp-based targeting of DLPFC. These standard treatments are only modestly effective, even in the general MDD population (17, 24–31).”
In the citing paper
“rTMS of the left side of the dorsolateral prefrontal cortex (DLPFC) at 10 Hz is a well-tolerated, evidence-based treatment for TRD.5”
In the citing paper
“While this intensity is consistent with current recommendations for standard rTMS,5 there is no current consensus on the optimal intensity for TBS and other studies have used lower intensities.12”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Wassermann, E. M. (1998) · Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section · doi:10.1016/s0168-5597(97)00096-8 · Cited by 2,293
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Self-citationUsing the International 10-20 EEG System for Positioning of Transcranial Magnetic Stimulation
Herwig, U., Satrapi, P., & Schönfeldt-Lecuona, C. (2003) · Brain Topography · doi:10.1023/b:brat.0000006333.93597.9d · Cited by 1,098
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 1×
“…magnetic stimulation device package insert as well as in the US Food and Drug Administration (FDA) 510k application material. b In the study by George et al,10 patients underwent head magnetic resonance imaging with fiducials (vitamin E capsules), which resulted in 33.2% of patients having…”
BackgroundSelf-citation
Cited by
Items 201–300 of 690
Yuan, H., Liu, B., Li, F., Jin, Y., Zheng, S., Ma, Z., Wu, Z., Chen, C., Zhang, L., Gu, Y., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115533 · Cited by 23
“The number of pulses and intensity of stimulation are two key parameters of settings in TMS (Belsher et al., 2021; Isserles et al., 2013; McClintock et al., 2018).”
BackgroundThe effects of intermittent theta burst stimulation (iTBS) on resting-state brain entropy (BEN)
Liu, P., Song, D., Deng, X., Shang, Y., Ge, Q., Wang, Z., & Zhang, H. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00556 · Cited by 19
“In effective rTMS protocols for depression, excitatory TMS is typically applied to the L-DLPFC (as observed with subthreshold iTBS, which increased BEN in this region), whereas inhibitory TMS is applied to the R-DLPFC [123 – 125].”
Hebel, T., Abdelnaim, M. A., Deppe, M., Langguth, B., & Schecklmann, M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120922965 · Cited by 21
“Repetitive transcranial magnetic stimulation (rTMS) is now well established as an effective and generally safe treatment for depressive illness as demonstrated by multiple clinical trials (Berlim et al., 2014; Lefaucheur et al., 2014; McClintock et al., 2018; Rossi et al., 2009) and is one of the main treatment option…”
MethodSánchez-Cuesta, F. J., Arroyo-Ferrer, A., González‐Zamorano, Y., Vourvopoulos, A., Badia, S. B. I., Figuereido, P., Serrano, J. I., & Romero, J. P. (2021) · Medicina · doi:10.3390/medicina57080736 · Cited by 25
“Although up to date there are some consensus recommendations about dosing and parameters of rTMS in some clinical applications such as pain [9] and depression [10], there is no clear consensus about the recommended parameters in stroke due to the heterogeneity of the currently published studies [11].”
BackgroundMiuli, A., Sepede, G., Stigliano, G., Mosca, A., Carlo, F. D., d’Andrea, G., Lalli, A., Spano, M. C., Pettorruso, M., Martinotti, G., et al. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.477 · Cited by 27
Michel‐Flutot, P., Zholudeva, L. V., Randelman, M. L., Deramaudt, T. B., Mansart, A., Alvarez, J., Lee, K., Petitjean, M., Bonay, M., Lane, M. A., et al. (2021) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2021.103704 · Cited by 22
Hebel, T., Grözinger, M., Landgrebe, M., Padberg, F., Schecklmann, M., Schlaepfer, T. E., Schönfeldt‐Lecuona, C., Ullrich, H., Zwanzger, P., Langguth, B., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1995810 · Cited by 21
“In principal, composition of tattoos can be obtained from the artist (McClintock et al. 2018), but this is often not feasible in everyday routine.”
BackgroundInfluentialLi, X., Lu, T., Yu, H. Z., Shen, J., Chen, Z., Yang, X., Huang, Z., Yang, Y., Feng, Y., Zhou, X., et al. (2022) · Neural Plasticity · doi:10.1155/2022/2036736 · Cited by 25
“In addition, positive effects of rTMS on depression were confirmed by some clinical controlled studies and expert consensus [71], and the optimal stimulation dose was recommended as double 900 pulses on the right side or double 1500 pulses on the left side to maximize the antidepressant effect [4].”
BackgroundKavanaugh, B. C., Fukuda, A. M., Gemelli, Z. T., Thorpe, R. V., Tirrell, E., Vigne, M. M., Jones, S. R., & Carpenter, L. L. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.10.024 · Cited by 18
Self-citationFukuda, A. M., Hindley, L. E., Kang, J. W. D., Tirrell, E., Tyrka, A. R., Ayala, A., & Carpenter, L. L. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001523 · Cited by 21
Self-citationLiu, Q., Sun, H., Hu, Y., Wang, Q., Zhao, Z., Dong, D., & Shen, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.842947 · Cited by 20
“Food and Drug Administration (FDA) for the treatment of major depression (9), migraine with aura (10), obsessive– compulsive disorder (11, 12), and smoking addiction (13).”
BackgroundToffanin, T., Folesani, F., Ferrara, M., Murri, M. B., Zerbinati, L., Caruso, R., Nanni, M. G., Koch, G., Fadiga, L., Palagini, L., et al. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.10.001 · Cited by 22
Effects of non-invasive brain stimulation in dystonia: a systematic review and meta-analysis
Morrison-Ham, J., Clark, G. M., Ellis, E. G., Cerins, A., Joutsa, J., & Enticott, P. G. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221138144 · Cited by 20
Depression core network-based individualized targeting for transcranial magnetic stimulation
Raij, T. T., Komulainen, E., Aydogan, D. B., Pamilo, S., Isometsä, E. T., & Raij, T. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.03.005 · Cited by 24
“In MDD patients failing to respond to first-line treatments, TMS of the dorsolateral prefrontal cortex (DLPFC) is an established and well-tolerated treatment [2].”
BackgroundZhou, C., Chen, Y., Xue, S., Shi, Q., Guo, L., Yu, H., Xue, F., Cai, M., Wang, H., & Peng, Z. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14287 · Cited by 18
“34 TMS could improve depressive symptoms and prevent the relapse of depressive episodes effectively in depression patients who have not responded to a full course of antidepressants.”
BackgroundMakale, M. T., Abbasi, S., Nybo, C., Keifer, J., Christman, L. A., Fairchild, J. K., Yesavage, J. A., Blum, K., Gold, M. S., Baron, D. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18943 · Cited by 22
Gonsalves, M. A., White, T. L., Barredo, J., DeMayo, M. M., DeLuca, E., Harris, A. D., & Carpenter, L. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-023-02715-9 · Cited by 22
Self-citationTan, V., Jeyachandra, J., Ge, R., Dickie, E. W., Gregory, E., Vanderwal, T., Vila‐Rodriguez, F., & Hawco, C. S. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.07.051 · Cited by 16
Evaluation of the Beam-F3 method for locating the F3 position from the 10–20 international system
Fabregat‐Sanjuan, A., Pàmies‐Vilà, R., & Pascual‐Rubio, V. (2022) · Brain stimulation · doi:10.1016/j.brs.2022.07.002 · Cited by 17
“Although this information is important for identifying a true F3 scalp landmark, there is no direct evidence to suggest that one DLPFC target is therapeutically superior to any other for rTMS.”
BackgroundHebel, T., Abdelnaim, M. A., Deppe, M., Kreuzer, P. M., Mohonko, A., Poeppl, T. B., Rupprecht, R., Langguth, B., & Schecklmann, M. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01287-3 · Cited by 18
Spitz, N. A., Eyck, P. T., Nizar, K., Boes, A. D., & Trapp, N. T. (2022) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000611 · Cited by 20
McClintock, S. M., Kallioniemi, E., Martin, D. M., Kim, J. U., Weisenbach, S. L., & Abbott, C. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180031 · Cited by 21
Self-citationWang, Z., Liu, Q., Li, D., Wei, L., Chu, E., Bao, Y., Liu, Z., Jin, L., Chen, X., & Zhao, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-02443-8 · Cited by 16
“Although consensus recommendations for rTMS use in treating major depressive disorder exist 18,19 , there is limited documentation on its application for stroke-related upper limb spasticity, possibly due to an incomplete understanding of the underlying mechanisms.”
Qin, Y., Tong, X., Li, W., Zhang, L., Zhang, Y., Li, X., Yang, J., Qin, K., Lei, D., Gong, Q., et al. (2021) · Brain Topography · doi:10.1007/s10548-021-00848-y · Cited by 18
Ahmadpanah, M., Amini, S., Mazdeh, M., Haghighi, M., Soltanian, A. R., Jahangard, L., Keshavarzi, A., & Brand, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072525 · Cited by 17
“For individuals with MDD, recent studies showed that rTMS produced changes in neural glutamate concentrations [55].”
ResultTranscranial Magnetic Stimulation as a Therapy for Migraine: An Overview of Systematic Reviews
Shen, M., Li, C., Wei, X., Zhang, L., Li, Y., Wu, H., Zhang, X., Dong, Z., Gao, S., Ma, Y., et al. (2023) · Journal of Pain Research · doi:10.2147/jpr.s416993 · Cited by 17
“The most common side effects of TMS and rTMS are mild headache, scalp discomfort, and temporary hearing impairment.(8,9) In recent years, neuroregulation devices, such as transcranial magnetic stimulation (TMS) has gained wide recognition as an option for treating migraines.”
BackgroundDevelopment and validation of a 3D-printed neuronavigation headset for therapeutic brain stimulation
Mansouri, F., Mir-Moghtadaei, A., Niranjan, V., Wu, J. S., Akhmedjanov, D., Nuh, M., Cairo, T., Giacobbe, P., Zariffa, J., & Downar, J. H. (2018) · Journal of Neural Engineering · doi:10.1088/1741-2552/aacb96 · Cited by 16
Antidepressant efficacy and side effect burden: an updated guide for clinicians
Kutzer, T., Dick, M., Scudamore, T., Wiener, M., & Schwartz, T. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-2 · Cited by 19
Schaffer, D. R., Okhravi, H. R., & Neumann, S. A. (2021) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acaa095 · Cited by 16
Bhattacharyya, P. K., Anand, A., Lin, J. Y., & Altinay, M. I. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.665347 · Cited by 20
“Thus, additional research is needed to establish an imaging biomarker that can be used to predict the success of rTMS treatment using a standard 10-Hz (40, 41) 4- to 6-week protocol in the adult population.”
BackgroundThatikonda, N. S., Vinod, P., Balachander, S., Bhaskarpillai, B., Arumugham, S. S., & Reddy, Y. C. J. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221121112 · Cited by 22
“Multiple meta-analyses indicate that rTMS is helpful in treatment-resistant OCD.11–13 rTMS protocols for OCD target different cortical regions including supplementary motor area (SMA), dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OFC) and dorsomedial prefrontal cortex (DMPFC). rTMS has also been found…”
MethodInfluentialSackeim, H. A., Dibué, M., Bunker, M. T., & Rush, A. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s286977 · Cited by 15
Sippel, L. M., Hamblen, J. L., Kelmendi, B., Alpert, J. E., Carpenter, L. L., Grzenda, A. L., Kraguljac, N. V., McDonald, W. M., Rodríguez, C. I., Widge, A. S., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230950 · Cited by 18
Self-citationBarnes, R., Skvarc, D., Fitzgerald, P. B., Berk, M., Dean, O. M., Dodd, S., Schriemer, T., & Singh, A. B. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110820 · Cited by 18
“A course usually lasts for 4–6 weeks of daily sessions, given in the inpatient or outpatient setting (McClintock et al., 2017).”
Qiu, M., Wang, R., Shen, Y., Hu, Z., & Zhang, Y. (2023) · The Cerebellum · doi:10.1007/s12311-023-01628-z · Cited by 15
“…magnetic stimulation (rTMS), a noninvasive and convenient cranial stimulation technique, is commonly used as a neurorehabilitation therapy for conditions such as depression [12], anxiety disorders [13], Parkinson’s disease [14], and migraine [15], among other neuropsychiatric disorders [16].”
Rakesh, G., Cordero, P., Khanal, R., Himelhoch, S. S., & Rush, C. R. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.037 · Cited by 21
Zhou, C., Gao, Y., Qiao, Q., Yang, Z., Zhou, W.-W., Ding, J., Xu, X., Qin, Y., & Zhong, C. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1475 · Cited by 16
Zhang, X., Zhu, L., Li, Y., Yu, H., Wang, T., & Chu, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02493-8 · Cited by 21
“Table 1 provides comprehensive management protocols for these potential complications [35].”
Tang, V. M., Foll, B. L., Blumberger, D. M., & Voineskos, D. (2021) · Brain Sciences · doi:10.3390/brainsci12010048 · Cited by 16
“Furthermore, the current standard for an adequate course of treatment is 20–30 sessions [30].”
BackgroundMethodInfluentialBright Light Therapy and rTMS; novel combination approach for the treatment of depression
Mania, I., & Kaur, J. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.06.002 · Cited by 15
Noda, Y., Wada, M., Mimura, Y., Taniguchi, K., Tarumi, R., Moriyama, S., Arai, N., Tsugawa, S., Thorpe, K. E., Daskalakis, Z. J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.15881 · Cited by 22
Effect of transcranial magnetic stimulation on treatment effect and immune function
Liu, S., Wang, X., Yu, R., & Sun, Y. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.08.104 · Cited by 17
Hyytiäinen, H. K., Boström, A. F., Asplund, K., & Bergh, A. (2022) · Animals · doi:10.3390/ani13010064 · Cited by 14
Can neuroimaging measures differentiate the disease course of anorexia nervosa? A systematic review
Bracké, K. F. M., Steegers, C. P. M., van der Harst, T., Dremmen, M. H. G., Vernooij, M. W., White, T. J. H., & Dieleman, G. C. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.059 · Cited by 14
Kong, Y., Zhou, J., Zhao, M., Zhang, Y., Tan, T., Xu, Z., Hou, Z., Yuan, Y., Tan, L., Song, R., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.024 · Cited by 14
Massé-Leblanc, C., Jodoin, V. D., Nguyen, D. K., Fournier‐Gosselin, M., Stip, É., Lespérance, P., & Miron, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115685 · Cited by 17
Thai, M., Nair, A. U., Klimes‐Dougan, B., Albott, C. S., Silamongkol, T., Corkrum, M., Hill, D. C., Roemer, J. W., Lewis, C. P., Croarkin, P. E., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.061 · Cited by 15
N100 as a response prediction biomarker for accelerated 1 Hz right DLPFC-rTMS in major depression
Sheen, J., Mazza, F., Momi, D., Miron, J., Mansouri, F., Russell, T., Zhou, R., Hyde, M., Fox, L., Voetterl, H., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.131 · Cited by 15
Kearney-Ramos, T. E., & Haney, M. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110290 · Cited by 12
Caparelli, E. C., Schleyer, B., Zhai, T., Gu, H., Abulseoud, O. A., & Yang, Y. (2022) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2022.03.002 · Cited by 15
Zheng, W., Lan, X.-J., Qin, Z.-J., Yang, X.-H., & Shi, Z.-M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1111754 · Cited by 19
Michael, J. A., & Kaur, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.016 · Cited by 15
Yan, J., Zhang, F., Niu, L., Wang, X., Lu, X., Ma, C., Zhang, C., Song, J., & Zhang, Z. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.020 · Cited by 17
Aoun, M. A., Meek, B. P., & Modirrousta, M. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.07.007 · Cited by 15
Tang, V. M., Goud, R., Zawertailo, L. A., Selby, P. L., Coroiu, A., Sloan, M. E., Chenoweth, M. J., Buchman, D. Z., Ibrahim, C., Blumberger, D. M., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115340 · Cited by 15
Lewis, C. P., Nakonezny, P. A., Sonmez, A. I., Özger, C., Garzon, J. F., Camsari, D. D., Yuruk, D., Romanowicz, M., Shekunov, J., Zaccariello, M. J., et al. (2024) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.08.487 · Cited by 18
Transcranial Direct Current Stimulation (tDCS) in Anxiety Disorders
Vicario, C. M., Salehinejad, M. A., Avenanti, A., & Nitsche, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-43356-7_21 · Cited by 14
“Considering that daily stimulation over 4–6 weeks is required in order to achieve a clinically significant effects of rTMS in depression [81, 82], it might well be that most of the clinical tDCS studies conducted so far are relevantly underpowered.”
BackgroundDiao, Y., Geng, M., Fu, Y., Wang, H., Liu, C., Gu, J., Dong, J., Mu, J., Liu, X., & Wang, C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.028 · Cited by 14
Hammad, A. B., Elhamrawy, E. A., Abdel‐Tawab, H., Shafik, M. A., Sallam, Y. A. N., Elzomor, H. M., & Bahbah, E. I. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106554 · Cited by 17
Lechner, W. V., Philip, N. S., Kahler, C. W., Houben, K., Tirrell, E., & Carpenter, L. L. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac183 · Cited by 12
Self-citationWeissman, C. R., Bermudes, R. A., Voigt, J. D., Liston, C. M., Williams, N., Blumberger, D. M., Fitzgerald, P. B., & Daskalakis, Z. J. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22com14575 · Cited by 18
REAC Neuromodulation Treatments in Depression, Anxiety and Stress. A Comparative Retrospective Study
Barcessat, A. R. P., Bittencourt, M. N., Gonçalves, R. G., Cruz, A. V. G. D. O., Pereira, J. A. C., Bechelli, F., & Rinaldi, A. (2020) · Psychology Research and Behavior Management · doi:10.2147/prbm.s287143 · Cited by 14
Miron, J., Hyde, M., Fox, L., Sheen, J., Voetterl, H., Mansouri, F., Jodoin, V. D., Zhou, R., Dees, S., Mir-Moghtadaei, A., et al. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100077 · Cited by 16
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
Psiuk, D., Nowak, E., Cholewa, K., Łopuszańska, U., & Samardakiewicz, M. (2021) · Life · doi:10.3390/life11080765 · Cited by 16
Stone, K. D., Dimitropoulos, G., & MacMaster, F. P. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/w7v2f · Cited by 24
Godfrey, K., Douglass, H. M., Erritzøe, D., Muthukumaraswamy, S. D., Nutt, D. J., & Sumner, R. L. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111455 · Cited by 19
Cano, M., Lee, E. G., Polanco, C., Barbour, T. A., Ellard, K. K., Andreou, B., Uribe, S., Henry, M., Seiner, S. J., Cardoner, N., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.093 · Cited by 14
Michel‐Flutot, P., Lane, M. A., Lepore, A. C., & Vinit, S. (2023) · Cells · doi:10.3390/cells12111519 · Cited by 14
Frid, L. M., Keßler, U., Ousdal, O. T., Hammar, Å., Haavik, J., Riemer, F., Hirnstein, M., Ersland, L., Erchinger, V. J., Ronold, E. H., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05239-0 · Cited by 14
“The treatment typically requires daily TMS sessions of up to 3000 pulses for four to six weeks [44].”
BackgroundDellink, A., Hebbrecht, K., Zeeuws, D., Baeken, C., Fré, G. D., Bervoets, C., Witte, S. D., Sabbe, B., Morrens, M., & Coppens, V. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.078 · Cited by 14
Wada, M., Nakajima, S., Taniguchi, K., Honda, S., Mimura, Y., Takemura, R., Thorpe, K. E., Tsugawa, S., Tarumi, R., Moriyama, S., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1474 · Cited by 15
Vlček, P., Bareš, M., Novák, T., & Brunovský, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00083 · Cited by 13
“, the centimeter rule), coil placement on F3 position according to the International 10–20 system, use of stereotactic frames, and neuroimage-guided frameless positioning technologies (90) which can increase the response rate.”
MethodSleep predicts the response to rTMS and CBT in patients with OCD: an open label effectiveness study
Gajadien, P., Postma, T. S., van Oostrom, I., Scheepstra, K. W. F., van Dijk, H., Sack, A. T., van den Heuvel, O. A., & Arns, M. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100353 · Cited by 15
Steward, B. A., Bakir, A. A., Martin, D. M., Dokos, S., & Loo, C. K. A. (2020) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2020.111157 · Cited by 15
Slow repetitive transcranial magnetic stimulation in refractory juvenile myoclonic epilepsies
Özek, S. Ü., Gürses, C., Bebek, N., Baykan, B. B., Gökyiğit, A., & Öge, A. E. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107479 · Cited by 10
Humaira, A., Gao, S., Gregory, E., Ridgway, L., Blumberger, D. M., Downar, J. H., Daskalakis, Z. J., Ainsworth, N. J., Wu, L., Butterfield, M., et al. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.07.015 · Cited by 11
“Each participant's resting motor threshold (RMT) was determined by use of visual observation in accordance with standard clinical practice [16].”
MethodChen, M., Cheng, C., Li, C., Tsai, S., Lin, W., Bai, Y., & Su, T. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114749 · Cited by 13
Accelerated sequential bilateral theta-burst stimulation in major depression: an open trial
Ramasubbu, R., Brown, E. C., Selby, B., McGirr, A., Cole, J., Hassan, H., & McAusland, L. B. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01648-0 · Cited by 10
Tang, V. M., Ibrahim, C., Rodak, T., Goud, R., Blumberger, D. M., Voineskos, D., & Foll, B. L. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105477 · Cited by 12
Bellini, B. B., Scholz, J. R., Abe, T. O., Arnaut, D., Tonstad, S., Alberto, R. L., Gaya, P. V., de Moraes, I. R. A., Teixeira, M. J., & Marcolin, M. A. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110997 · Cited by 14
Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults
Brown, R. E., Cherian, K. N., Jones, K. L., Wickham, R. E., Gomez, R. G., & Sahlem, G. L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015040.pub2 · Cited by 29
Yang, Y., Chen, J., Yu, M., Xiong, C., Zhang, R., & Jiang, G. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116340 · Cited by 12
Patricio, P., Roy, J., Macedo, L. G., Roy, M., Léonard, G., Hodges, P. W., & Massé‐Alarie, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045504 · Cited by 13
Adjunctive Nonconvulsive Electrotherapy for Patients with Depression: a Systematic Review
Cai, D.-B., Zhou, H., Liang, W., Gu, L.-M., He, M., Huang, X., Shi, Z.-M., Hou, H.-C., & Zheng, W. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09936-5 · Cited by 11
Pallanti, S., Marras, A. M., Dickson, S. L., Adan, R. A. H., Vieta, E., Osso, B. D., Arango, C., Fusar‐Poli, P., Soriano‐Mas, C., Carmi, L., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.002 · Cited by 13
Li, J., Cui, L., & Li, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1038312 · Cited by 13
“A significant treatment effect was not found when using sub-rTMS for TRD, compared to the sham control, which supports the use of suprathreshold stimulation (RMT > 100”
BackgroundInfluentialRobotic transcranial magnetic stimulation in the treatment of depression: a pilot study
Shin, H., Jeong, H. S., Ryu, W., Lee, G. S., Lee, J., Kim, D., Song, I., Chung, Y., & Lee, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-41044-1 · Cited by 18
“Coil positioning using a robot has some advantages in an rTMS treatment session: (1) the placement of the coil by the robot is more accurate than by hand; (2) it is faster and more consistent than the control by hand despite the reduced speed of the robot in consideration of the safety of the patient; (3) the repeatab…”
BackgroundMethodTang, S. J., Holle, J., Dadario, N. B., Lesslar, O., Teo, C., Ryan, M., Sughrue, M. E., & Yeung, J. T. (2023) · Brain and Behavior · doi:10.1002/brb3.3268 · Cited by 10
Hulla, R., & Dougall, A. L. (2019) · Cephalalgia Reports · doi:10.1177/2515816319889971 · Cited by 12
“A possible novel treatment method that has less severe side effects than commonly prescribed drugs for migraine treatment is repetitive transcranial magnetic stimulation (rTMS).(31) rTMS has demonstrated efficacy in treating illnesses that have shared pathology and are often comorbid with migraine, including depressio…”
Cepeda, M. S., Kern, D. M., & Canuso, C. M. (2021) · Depression and Anxiety · doi:10.1002/da.23138 · Cited by 11
“TMS devices received FDA clearance for adults with MDD who had not seen success with at least one antidepressant in 2008 (McClintock et al., 2018).”
MethodSvěrák, T., Linhartová, P., Gajdoš, M., Kuhn, M., Látalová, A., Lamoš, M., Ustohal, L., & Kašpárek, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.770353 · Cited by 18
Using Remotely Supervised At-Home TES for Enhancing Mental Resilience
Paneva, J., Leunissen, I., Schuhmann, T., de Graaf, T. A., Joensson, M. G., Onarheim, B., & Sack, A. T. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.838187 · Cited by 12
“The use of rTMS as a therapy for treatment resistant depression (TRD) has received CE and Food and Drug Administration (FDA) approval and is increasingly widely adopted in clinical practice (McClintock et al., 2018).”
Backgroundde Andrade, D. C., & Valiengo, L. D. C. L. (2025) · European Journal of Pain · doi:10.1002/ejp.70077 · Cited by 11
Yang, Z., & Zhou, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04864-z · Cited by 11
“rTMS was applied to the prefrontal cortex and induced magnetic fields to depolarize potential neurons and modulate neural circuits involved in mood regulation and depressive symptoms [35].”
MethodClinical application of transcranial magnetic stimulation for functional bowel disease
Li, G., Jin, B., & Fan, Z. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1213067 · Cited by 10
“TMS has been widely used in medical treatment for epilepsy (26), Parkinson’s (27), depression (28), neuropathic pain (29), and stroke (30),but there are”
MethodYe, S., Chen, C., Wei, B., Zhan, J., Li, Y.-H., Zhang, C., Huang, J.-J., & Yang, Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1446849 · Cited by 13
Tao, X., Jing, Z. W., Yuan, W. K., Yun, G. H., Fang, X. J., & Sheng, L. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1504727 · Cited by 14
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Lau, C. I., Chen, W., & Walsh, V. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.05.018 · Cited by 11
Cantù, F., Schiena, G., Sciortino, D., Consoli, L. D., Delvecchio, G., Maggioni, E., & Brambilla, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.798847 · Cited by 13
“The exclusion criteria were: (a) diagnosis of schizophrenia or other psychotic disorders; (b) diagnosis of neurological disorders; (c) diagnosis of substance use disorder in the last 6 months, according to DSM-5 criteria; (d) contraindications to TMS according to the Consensus Recommendations for the safe and effectiv…”
Method
Metadata
- Authors
- McClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., Krystal, A. D., Sampson, S. M., Morales, O., Nelson, B. G., Latoussakis, V., George, M. S., Lisanby, S. H., & on behalf of both the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- Duke University (US)
- Johns Hopkins University (US)
- Butler Hospital (US)
- Emory University (US)
- Weill Cornell Medicine (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- American Psychiatric Association (US)
- Mayo Clinic (US)
- Harvard University (US)
- University of Minnesota (US)
- Medical University of South Carolina (US)
- Corresponding author
- McClintock, Shawn M.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2018-02-21
- Volume
- 79
- Issue
- 1
- Pages
- 35-48
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC5846193
- OpenAlex
- W2617605873
- Cited by
- 693
- References
- 120
- Citations by year
- 2026: 77 · 2025: 94 · 2024: 108 · 2023: 82 · 2022: 85 · 2021: 98 · 2020: 66 · 2019: 54 · 2018: 22
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Institute of Mental Health (K23MH087739)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- repetitive transcranial magnetic stimulation, major depressive disorder, depression treatment, expert consensus recommendations, antidepressant treatment
- MeSH terms
- Contraindications, Major Depressive Disorder, Humans, Transcranial Magnetic Stimulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.